Preanalytical considerations in drug assays in clinical pharmacokinetic studies.

Preanalytical considerations in drug assays in clinical pharmacokinetic studies. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Preanalytical considerations in drug assays in clinical pharmacokinetic studies. Abstract Text:

Many hospital pharmacy laboratories undertake drug analysis in biological fluids for the production of pharmacokinetic data. The success of such an undertaking very much depends on the selection of a suitable analytical method and a proper approach to sample collection and handling. This paper surveys the main types of biological specimens taken from the patients for pharmacokinetic drug analysis and discusses factors that affect them during or subsequent to their removal. Guidelines are provided in specimen handling and dealing with many problems which could arise prior to actual analysis. By its very nature this paper brings in many disciplines, the full details of which are well beyond its scope, however, some discussion on pharmacokinetic and bioavailability methods in relation to sampling procedures is included to put the matter into a proper perspective.

Preanalytical considerations in drug assays in clinical pharmacokinetic studies. Publishing Authors By Initials

For similar biochemical phenomena, metabolism, and nutrition: metabolism: pharmacokinetics research abstracts see: biochemical phenomena, metabolism, and nutrition: metabolism: pharmacokinetics research

PUBMED ID PMID:

MEDLINE DATE:

Preanalytical considerations in drug assays in clinical pharmacokinetic studies. Journal Published:

PUBLICATION TYPE: Review

Journal: Journal of clinical pharmacy and therapeutics

VOLUME: 14

Page Numbers: 285-95

Journal Abbreviation: J Clin Pharm Ther

ISSN: 0269-4727

DAY: 28

MONTH: Aug

YEAR: 1989

Preanalytical considerations in drug assays in clinical pharmacokinetic studies. Information

Number of References: 42

LANGUAGE: eng

NlmUniqueID: 8704308

Preanalytical considerations in drug assays in clinical pharmacokinetic studies. Keywords Mesh Terms:

KEYWORDS: Pharmacokinetics

MESH TERMS: analysis

Chemical & Substance for Abstract: Preanalytical considerations in drug assays in clinical pharmacokinetic studies. Information

Substance Name: Pharmaceutical Preparations

Registry Number: 0

Grant and Affiliation Information for Preanalytical considerations in drug assays in clinical pharmacokinetic studies.

AFFILIATION: Department of Pharmacy, General Infirmary, Leeds, Yorkshire, U.K.

Country: ENGLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Pharm Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Preanalytical considerations in drug assays in clinical pharmacokinetic studies Related Publications

• An Evidence-based Approach to the Evaluation and Management of Hip Pain In Children.
• Androgen-regulated formation and degradation of gap junctions in androgen-responsive human prostate cancer cells.
• Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin.
• Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer.
• Clinical experience with substrate reduction therapy.
• Common carotid artery wall thickness and external diameter as predictors of prevalent and incident cardiac events in a large population study.
• Cyclosilicate nanocomposite: a novel resorbable bioactive tissue engineering scaffold for BMP and bone-marrow cell delivery.
• Differential expression of prohibitin is correlated with dual action of Vitamin D as a proliferative and antiproliferative hormone in breast epithelial cells.
• Disaster and mass casualty management in a hospital: How well are we prepared?
• Distribution of brain metastases in relation to the hippocampus: implications for neurocognitive functional preservation.
• Epidemiology and natural history of Gaucher's disease.
• Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation.
• Generalized expectancies for negative mood regulation predict change in anxiety and depression among college students.
• Gonorrhea and Chlamydia in emergency departments: screening, diagnosis, and treatment.
• High-risk acute coronary syndrome patient and cardiac biomarkers in the emergency department: where do we stand?
• Humoral immune responses to peptides derived from the beta-amyloid peptide C-terminal sequence.
• Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
• Ixocarpalactone A isolated from the Mexican tomatillo shows potent antiproliferative and apoptotic activity in colon cancer cells.
• Mechanism of action and delivery possibilities for TGFbeta1 in the treatment of myocardial ischemia.
• N-linked glycosylation of CD38 is required for its structure stabilization but not for membrane localization.
• Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.
• Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.
• Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119).
• Regulatory role of endothelium in the expression of genes affecting arterial calcification.
• Retinoic acid-induced CD38 antigen promotes leukemia cells attachment and interferon-gamma/interleukin-1beta-dependent apoptosis of endothelial cells: implications in the etiology of retinoic acid syndrome.
• Stress among family caregivers of older persons in Singapore.
• The role of statins in endothelial dysfunction in hypertension.
• The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: development of a novel therapeutic vaccine candidate.
• Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells.
• alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins.